Medicinova Inc (NASDAQ:MNOV) does about 39.29K shares in volume on a normal day but saw 2071089 shares change hands in the recent trading day. The company now has a market cap of 111.83M USD. Its current market price is $2.28, marking an increase of 49.02% compared to the previous close of $1.53. The 52 week high reached by this stock is $2.16 whilst the lowest price level in 52 weeks is $1.12.
Medicinova Inc (MNOV) has a 20-day trading average at $1.7200 and the current price is 5.56% off the 52-week high compared with 103.57% distance from its 52-week low. The 50-day simple moving average of the closing price is $1.8300 and its 200-day simple moving average is $1.4800. If we look at the stock’s price movements over the week, volatility stands at 14.96%, which decreases to 7.88% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 71.84 to suggest the stock is overbought.
The consensus objective for the share price is $10.00, suggesting that the stock has a potential upside of 77.2% over the period.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on March 10, 2021 when Maxim Group initiated the stock to “Buy” and issued a price target of $15. B. Riley FBR Inc. initiated its price target at $22.
The current price level is 32.56%, 24.74%, and 53.93% away from its SMA20, SMA50, and SMA200 respectively, with the MNOV price moving below the 50-day SMA on current market day. Medicinova Inc (MNOV) stock is up 41.61% over the week and 28.81% over the past month. Its price is 52.00% year-to-date and 28.09% over the past year.
The stock last released its quarterly earnings report for quarter ended 6/30/2024, with the company’s earnings per share (EPS) of -0.01 above consensus estimates by 0.07. The company’s next earnings report forecasts estimating quarterly EPS at 0 and 0 for whole year.
To reach the target analysts have set, the stock logically needs to grow 77.2 percent from here.
The company has a return on investment of -14.15% and return on equity of -13.32%. The beta has a value of 0.76. Price to book ratio is 1.95 and price to sales ratio is 111.83.
